Search Results - "Kater, A. P."

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study by Rawstron, A C, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, R M, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, A P, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, J L, Stetler-Stevenson, M, Yuan, C, Broome, H E, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, C M, Emerson, R, Robins, H S, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, T J, Wierda, W G, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P

“…In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing…”
Get full text

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation by Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P., Pospisilova, S.

“…In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with…”
Get full text

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia by Pospisilova, S, Gonzalez, D, Malcikova, J, Trbusek, M, Rossi, D, Kater, A P, Cymbalista, F, Eichhorst, B, Hallek, M, Döhner, H, Hillmen, P, van Oers, M, Gribben, J, Ghia, P, Montserrat, E, Stilgenbauer, S, Zenz, T

“…Recent evidence suggests that – in addition to 17p deletion – TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data…”
Get full text

The impact of SF3B1 mutations in CLL on the DNA-damage response by te Raa, G D, Derks, I A M, Navrkalova, V, Skowronska, A, Moerland, P D, van Laar, J, Oldreive, C, Monsuur, H, Trbusek, M, Malcikova, J, Lodén, M, Geisler, C H, Hüllein, J, Jethwa, A, Zenz, T, Pospisilova, S, Stankovic, T, van Oers, M H J, Kater, A P, Eldering, E

“…Mutations or deletions in TP53 or ATM are well-known determinants of poor prognosis in chronic lymphocytic leukemia (CLL), but only account for approximately…”
Get full text

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia by Hengeveld, P. J., Schilperoord-Vermeulen, J., van der Klift, M. Y., Dubois, J. M. N., Kolijn, P. M., Kavelaars, F. G., Rijken, M., Dobber, J. A., Nasserinejad, K., Kersting, S., Westerweel, P. E., Kater, A. P., Langerak, A. W., Levin, M-D.

Get full text

ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia by Tonino, S H, van Laar, J, van Oers, M H, Wang, J Y, Eldering, E, Kater, A P

“…In recent years considerable progress has been made in treatment strategies for chronic lymphocytic leukemia (CLL). However, the disease remains incurable…”
Get full text

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C.U., Kater, A.P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M., Mey, U.

“…•These updated ESMO Clinical Practice Guidelines provide key recommendations on the management of chronic lymphocytic leukaemia (CLL)•Authorship includes a…”
Get full text

Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989–2008 by van den Broek, E.C, Kater, A.P, van de Schans, S.A.M, Karim-Kos, H.E, Janssen-Heijnen, M.L.G, Peters, W.G, Nooijen, P.T.G.A, Coebergh, J.W.W, Posthuma, E.F.M

“…Abstract We present trends in incidence, early treatment and survival of Chronic Lymphocytic Leukaemia (CLL) between 1989 and 2008, based on population-based…”
Get full text

R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia by Tonino, S H, van Gelder, M, Eldering, E, van Oers, M H, Kater, A P

Get full text

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition by Slinger, E, Thijssen, R, Kater, A P, Eldering, E

“…The clinical success of B-cell receptor (BCR) signaling pathway inhibitors in chronic lymphocytic leukemia (CLL) is attributed to inhibition of adhesion in and…”
Get full text

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia by Eichhorst, B, Ghia, P, Niemann, C U, Kater, A P, Gregor, M, Hallek, M, Jerkeman, M, Buske, C

Get more information

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia by Blume, C J, Hotz-Wagenblatt, A, Hüllein, J, Sellner, L, Jethwa, A, Stolz, T, Slabicki, M, Lee, K, Sharathchandra, A, Benner, A, Dietrich, S, Oakes, C C, Dreger, P, te Raa, D, Kater, A P, Jauch, A, Merkel, O, Oren, M, Hielscher, T, Zenz, T

“…Mutations of the tumor suppressor p53 lead to chemotherapy resistance and a dismal prognosis in chronic lymphocytic leukemia (CLL). Whereas p53 targets are…”
Get full text

Monoclonal B-cell lymphocytosis: Recommendations from the Dutch Working Group on CLL for daily practice by TE RAA, G. D, VAN OERS, M. H, KATER, A. P

“…Monoclonal B-cell lymphocytosis (MBL) is defined by the presence of small B-cell clones in asymptomatic individuals. Usually, MBL cells are characterised by a…”
Get full text

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling by van Attekum, MHA, Terpstra, S, Reinen, E, Kater, AP, Eldering, E

“…Survival of chronic lymphocytic leukemia (CLL) cells is mainly driven by interactions within the lymph node (LN) microenvironment with bystander cells such as…”
Get full text

Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011 by KATER, A. P, WITTEBOL, S, CHAMULEAU, M. E. D, VAN GELDER, M, VAN OERS, M. H. J

“…One of the principal responsibilities of the Chronic Lymphocytic Leukaemia (CLL) Working Party of the Dutch/Belgium Haemato-Oncology Foundation for Adults in…”
Get full text

Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation by MACKUS, W. J. M, KATER, A. P, ELDERING, E, GRUMMELS, A, EVERS, L. M, HOOIJBRINK, B, KRAMER, M. H. H, CASTRO, J. E, KIPPS, T. J, VAN LIER, R. A. W, VAN OERS, M. H. J

“…We investigated the apoptosis gene expression profile of chronic lymphocytic leukemia (CLL) cells in relation to (1) normal peripheral and tonsillar B-cell…”
Get full text

EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1 by Eichhorst, B., Eradat, H., Niemann, C. U., Oki, T., Kuznetsova, A., Rios, M., Valentin, R., Kater, A. P.

Get full text

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia by van Attekum, M H A, Terpstra, S, Slinger, E, von Lindern, M, Moerland, P D, Jongejan, A, Kater, A P, Eldering, E

“…Protective interactions with bystander cells in micro-environmental niches, such as lymph nodes (LNs), contribute to survival and therapy resistance of chronic…”
Get full text

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future by Spaargaren, M, de Rooij, M F M, Kater, A P, Eldering, E

“…The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise…”
Get full text

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL by Campanella, A., Capasso, A., Heltai, S., Taccetti, C., Albi, E., Herishanu, Y., Haggenburg, S., Chatzikonstantinou, T., Doubek, M., Kättström, M., Giannopoulos, K., Simkovic, M., Moreno, C., Massaia, M., Bumbea, H., Alshemmari, S., Ranghetti, P., Perotta, E., Martini, F., Sant'Antonio, E., Colia, M., Combi, C., Levi, S., Kater, A. P., Hazenberg, M., Nijhof, I. S., Hofsink, Q., Demosthenous, C., Kotaskova, J., Zaleska, J., Vrbacky, F., Raya, A. Mora, Bisogno, D., Tripoli, I. E., Popov, V. M., Roman, V., Stavroyianni, N., Karypidou, M., Scarano, E., Locatelli, M., Frenquelli, M., Scarfò, L., Stamatopoulos, K., Ghia, P.

“…Profound immune dysregulation and impaired response to the SARS‐CoV‐2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID‐19…”
Get full text